266 related articles for article (PubMed ID: 38449862)
21. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.
Liu J; Zhou G; Zhang L; Zhao Q
Front Immunol; 2019; 10():456. PubMed ID: 30941126
[TBL] [Abstract][Full Text] [Related]
22. Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges.
Zhi L; Su X; Yin M; Zhang Z; Lu H; Niu Z; Guo C; Zhu W; Zhang X
Cell Immunol; 2021 Nov; 369():104436. PubMed ID: 34500148
[TBL] [Abstract][Full Text] [Related]
23. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
Ren J; Zhao Y
Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
[TBL] [Abstract][Full Text] [Related]
24. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
[TBL] [Abstract][Full Text] [Related]
25. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
Wu HY; Cao CY
Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
[TBL] [Abstract][Full Text] [Related]
26. Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells.
Sterner RM; Cox MJ; Sakemura R; Kenderian SS
J Vis Exp; 2019 Jul; (149):. PubMed ID: 31380838
[TBL] [Abstract][Full Text] [Related]
27. CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges.
Chen M; Xu J; Zhou Y; Zhang S; Zhu D
Brief Funct Genomics; 2020 May; 19(3):183-190. PubMed ID: 31788683
[TBL] [Abstract][Full Text] [Related]
28. GMP-manufactured CRISPR/Cas9 technology as an advantageous tool to support cancer immunotherapy.
Caforio M; Iacovelli S; Quintarelli C; Locatelli F; Folgiero V
J Exp Clin Cancer Res; 2024 Mar; 43(1):66. PubMed ID: 38424590
[TBL] [Abstract][Full Text] [Related]
29. Review: Sustainable Clinical Development of CAR-T Cells - Switching From Viral Transduction Towards CRISPR-Cas Gene Editing.
Wagner DL; Koehl U; Chmielewski M; Scheid C; Stripecke R
Front Immunol; 2022; 13():865424. PubMed ID: 35784280
[TBL] [Abstract][Full Text] [Related]
30. CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer.
Khan A; Sarkar E
Cancer Treat Res Commun; 2022; 33():100641. PubMed ID: 36193597
[TBL] [Abstract][Full Text] [Related]
31. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.
Ghaffari S; Khalili N; Rezaei N
J Exp Clin Cancer Res; 2021 Aug; 40(1):269. PubMed ID: 34446084
[TBL] [Abstract][Full Text] [Related]
32. CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro.
Alishah K; Birtel M; Masoumi E; Jafarzadeh L; Mirzaee HR; Hadjati J; Voss RH; Diken M; Asad S
J Transl Med; 2021 Nov; 19(1):482. PubMed ID: 34838059
[TBL] [Abstract][Full Text] [Related]
33. Erratic journey of CRISPR/Cas9 in oncology from bench-work to successful-clinical therapy.
Sarkar E; Khan A
Cancer Treat Res Commun; 2021; 27():100289. PubMed ID: 33667951
[TBL] [Abstract][Full Text] [Related]
34. Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy.
Quazi S
Mol Biol Rep; 2022 Jul; 49(7):7069-7077. PubMed ID: 35122203
[TBL] [Abstract][Full Text] [Related]
35. CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy.
Ding S; Liu J; Han X; Tang M
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003514
[TBL] [Abstract][Full Text] [Related]
36. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
37. Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies.
Xu Q; Zhang Z; Zhao L; Qin Y; Cai H; Geng Z; Zhu X; Zhang W; Zhang Y; Tan J; Wang J; Zhou J
J Control Release; 2020 Oct; 326():455-467. PubMed ID: 32711027
[TBL] [Abstract][Full Text] [Related]
38. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies.
Chen X; Tan B; Xing H; Zhao X; Ping Y; Zhang Z; Huang J; Shi X; Zhang N; Lin B; Cao W; Li X; Zhang X; Li L; Jiang Z; Zhang M; Li W; Liu M; Du B; Zhang Y
Cancer Immunol Immunother; 2024 Jan; 73(1):13. PubMed ID: 38231412
[TBL] [Abstract][Full Text] [Related]
40. CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool.
Shojaei Baghini S; Gardanova ZR; Abadi SAH; Zaman BA; İlhan A; Shomali N; Adili A; Moghaddar R; Yaseri AF
Cell Mol Biol Lett; 2022 May; 27(1):35. PubMed ID: 35508982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]